IFN-I receptor deficient (IFNaR1−/−) recipient mice developed more severe GVHD, while treatment of allo-HSCT recipients with recombinant IFN-I ameliorated the course of GVHD5,6. Here, IFNAR1 is linked to graft versus host disease.